HRS-2189 clinical trials
Also written HRS-2189.
How each study uses HRS-2189 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-2189 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HRS-2189
- 2
Studies by the year they started
4 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 2 · Other 2
Shandong Suncadia Medicine Co., Ltd. (2) · Fudan University (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test HRS-2189.
- Jan 2027Study of HRS-2189 Combined HRS-5041 in Prostate CancerPhase 2 · Fudan University
Studies
Open first, then newest update. How each study uses HRS-2189 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07061210Written as HRS-2189
- Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruitingPhase 2Fudan UniversityNCT06738745Written as HRS-2189
- Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant TumorsRecruitingPhase 1Shandong Suncadia Medicine Co., Ltd.NCT05851092Written as HRS-2189 Tablets
- A Clinical Study Comparing the Bioavailability of HRS-2189 TabletsCompletedPhase 1Shandong Suncadia Medicine Co., Ltd.NCT07639905Written as HRS-2189 Tablet
Given beside what is tested · 3 — HRS-2189 is usual care or a partner of the new treatment
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06568094Written as HRS-2189 Tablets
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06974929Written as HRS-2189 Tablets
- A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06679036Written as HRS-2189